Onabotulinum toxin a for post-traumatic headache: A systematic review of case reports and case series
Abstract
Introduction Post-traumatic headache (PTH) is a debilitating condition following traumatic brain injury (TBI), leading to chronic pain and a significant reduction in quality of life. Onabotulinumtoxin A (OnaBTX-A), widely approved for chronic migraine treatment, has shown potential in reducing headache frequency and intensity in PTH cases. Still, its efficacy remains less studied in this population. Methods This systematic review examines four case reports and series involving a variety of patient populations, including athletes, military personnel, gunshot survivors, and a patient with severe TBI. These studies collectively investigate the effectiveness of OnaBTX-A in reducing PTH symptoms. Results OnaBTX-A was consistently associated with symptom relief in patients with PTH. A 15-year-old athlete reported complete resolution of headaches and reduced reliance on pain medication after treatment. Three gunshot survivors with both PTH and cervical dystonia showed 70% to 100% improvement with sustained benefits over 90-day injection intervals. In a case series of 64 military personnel with mild TBI, 64% experienced symptom improvement, particularly in mixed headache types. A 62-year-old woman suffering from chronic PTH for 5 years post-TBI achieved full pain relief, with an associated resolution of the “iron band” sensation, significantly enhancing her quality of life. Conclusion OnaBTX-A demonstrates promise as an effective and well-tolerated treatment for chronic PTH across…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.